The SPORE Career Development Program (CDP) prepares physicians and scientists for independent careers as investigators in translational research in prostate cancer. We have designed the CDP to form both an interdepartmental and an interinstitutional training ground to produce investigators who will become intellectual leaders in their fields of interest. By combining the research and academic resources available throughout Memorial Sloan-Kettering Cancer Center and at our affiliated institutions, we have a long tradition of successful fellowship training and faculty development for both internally and externally trained candidates. Recruiting and/or developing the career of new faculty members committed to translational research in prostate cancer is a centerpiece of our program, but in previous SPORE cycles we were equally focused on training and supporting senior research fellows who were committed to a career in translational research in prostate cancer. In accordance with changes to the current SPORE guidelines, we have reworked the specific aims of our Career Development Program. Our plan is to use the SPORE career development funds, supplemented with an equal amount of institutional funds, over the next 5 years to continue to recruit and develop the careers of junior faculty members and experienced investigators?from both basic research and clinical backgrounds?committed to translational research in prostate cancer.
Aim 1 : To recruit and/or develop the career of 1 or 2 junior faculty members or established investigators each year who are committed to translational research in prostate cancer Aim 2: To provide the scholarly basis for effective translational research in prostate cancer through a broad educational program in prostate cancer, emphasizing the knowledge base for conducting translational research through academic courses, scheduled conferences, and a program of invited speakers and visiting professors.

Public Health Relevance

concern, prostate cancer is the second deadliest cancer in men. The CDP plays a key role in recruiting and training exceptional scientific talent for translational research projects in prostate cancer.

Agency
National Institute of Health (NIH)
Type
Specialized Center (P50)
Project #
5P50CA092629-14
Application #
8730090
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
City
New York
State
NY
Country
United States
Zip Code
10065
Loeb, Stacy; Lilja, Hans; Vickers, Andrew (2016) Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol 26:459-65
Fleshner, Katherine; Assel, Melissa; Benfante, Nicole et al. (2016) Clinical Findings and Treatment Outcomes in Patients with Extraprostatic Extension Identified on Prostate Biopsy. J Urol 196:703-8
Carlsson, Sigrid V; de Carvalho, Tiago M; Roobol, Monique J et al. (2016) Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer 122:3386-3393
Zelefsky, Michael J; Poon, Bing Ying; Eastham, James et al. (2016) Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiother Oncol 118:85-91
Kent, Matthew; Penson, David F; Albertsen, Peter C et al. (2016) Successful external validation of a model to predict other cause mortality in localized prostate cancer. BMC Med 14:25
Scher, Howard I; Lu, David; Schreiber, Nicole A et al. (2016) Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol 2:1441-1449
Sood, Anup; Miller, Alexandra M; Brogi, Edi et al. (2016) Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight 1:
Danila, Daniel C; Samoila, Aliaksandra; Patel, Chintan et al. (2016) Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients. Cancer J 22:315-320
Braun, Katharina; Sjoberg, Daniel D; Vickers, Andrew J et al. (2016) A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Eur Urol 69:505-11
Preston, Mark A; Batista, Julie L; Wilson, Kathryn M et al. (2016) Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 34:2705-11

Showing the most recent 10 out of 424 publications